Cannabis Legalization: What Does it Mean for Public Health & Social Equity? | Beau Kilmer, PhD

This presentation is part of the 2020 State of the Art in Addiction Medicine conference which covers an expansion of treatment into correctional health, hospital consultation services and emergency rooms. It will cover how, despite the pandemic, telehealth can reach those who are isolated. It will address the worrisome trends in fentanyl, methamphetamine, tobacco and benzodiazepines use; legalization of cannabis, treatment updates for youth, cannabis and alcohol in pregnant women; and novel treatments such as non-benzodiazepines for alcohol withdrawal and psychedelics for substance use disorders.  

Learners cannot sign up for individual lectures, only for the full 2020 State of the Art in Addiction Medicine. Please contact CSAM (csam@csam-asam.org) if you have any questions about this online educational offering. 

Target Audience

Addiction medicine specialists who want an overview of the latest developments in the field and their relevance to clinical practice

  1. Primary care, psychiatry and other specialty field clinicians who want a better understanding of addiction and to improve their care of patients with unhealthy substance use
  2. Public policy makers, administrators and advocates who want an understanding of the current state of the field of addiction and its grater implications including towards prevention, access to care, integrated systems of care and healthcare technology
  3. Other healthcare professionals, including psychologists, therapists, nurses, and addiction counselors, who are involved in the treatment of patients with or at risk of substance use

Learning Objectives

  • Differentiate between commericial and non-commerical approaches to legalizing cannabis
  • Describe the various ways cannabis policy can influence social equity outcomes
  • Assess the emerging evidence on the effects of cannabis legalizaation on public health outcomes
Course summary
Available credit: 
  • 0.75 AMA Category 1
  • 0.75 Attendance
Course opens: 
11/13/2020
Course expires: 
11/13/2023
Cost:
$0.00
Part of: 
Clone of State of the Art in Addiction Medicine (2020)

Beau Kilmer, PhD

Beau Kilmer is director of the RAND Drug Policy Research Center and a senior policy researcher at the RAND Corporation. His research lies at the intersection of public health and public safety, with special emphasis on crime control, substance use, illicit markets, and public policy. 

Some of his current projects include analyzing the consequences of cannabis legalization (with a special focus on social equity); measuring the effect of 24/7 Sobriety programs on DUI, domestic violence, and mortality; facilitating San Francisco's Street-Level Drug Dealing Task Force; and evaluating the evidence and arguments made about implementing heroin-assisted treatment and supervised consumption sites in the United States. 

Kilmer's publications have appeared in leading journals such as New England Journal of Medicine and Proceedings of the National Academy of Sciences, and his commentaries have been published by CNN, Los Angeles Times, New York Times, Newsweek, San Francisco Chronicle, USA Today, Wall Street Journal, and other outlets. His coauthored book on cannabis legalization was published by Oxford University Press and his coauthored book on the future of fentanyl and other synthetic opioids was published by RAND. 

Kilmer received a National Highway Traffic Safety Administration Public Service Award for his “leadership and innovation in the areas of alcohol and drug-impaired driving program and policy research” and his coauthored work on 24/7 Sobriety received honourable mention for the Behavioural Exchange Award for Outstanding Research. He received his B.A. in international relations from Michigan State University, M.P.P. from UC Berkeley, and Ph.D. in public policy from Harvard University.

DISCLOSURE: No relevant financial relationships to disclose

Disclosure link: 
Faculty Disclosures

CSAM 
The California Society of Addiction Medicine (CSAM) is accredited by the California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.

CSAM designates this live educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™, Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Continuing education credit is available for psychologists, therapists, substance use counselors, nurses and physician assistants.

(see additional information on page for parent course)

Available Credit

  • 0.75 AMA Category 1
  • 0.75 Attendance

Price

Cost:
$0.00
Please login or register to take this course.